HK1131738A1 - Antisecretory protein for use in the treatment of compartment syndrome - Google Patents

Antisecretory protein for use in the treatment of compartment syndrome

Info

Publication number
HK1131738A1
HK1131738A1 HK09108961.9A HK09108961A HK1131738A1 HK 1131738 A1 HK1131738 A1 HK 1131738A1 HK 09108961 A HK09108961 A HK 09108961A HK 1131738 A1 HK1131738 A1 HK 1131738A1
Authority
HK
Hong Kong
Prior art keywords
treatment
compartment syndrome
tumour
antisecretory
antisecretory protein
Prior art date
Application number
HK09108961.9A
Other languages
English (en)
Inventor
Hans-Arne Hansson
Stefan Lange
Eva Jennische
Tomas Bergstroem
Original Assignee
Lantmaannen As Faktor Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lantmaannen As Faktor Ab filed Critical Lantmaannen As Faktor Ab
Publication of HK1131738A1 publication Critical patent/HK1131738A1/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/12Aerosols; Foams
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/02Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • A61P39/02Antidotes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Rheumatology (AREA)
  • Dispersion Chemistry (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
HK09108961.9A 2006-04-27 2009-09-29 Antisecretory protein for use in the treatment of compartment syndrome HK1131738A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0600933 2006-04-27
PCT/SE2007/000413 WO2007126363A2 (en) 2006-04-27 2007-04-27 Antisecretory protein for use in the treatment of compartment syndrome

Publications (1)

Publication Number Publication Date
HK1131738A1 true HK1131738A1 (en) 2010-02-05

Family

ID=38655929

Family Applications (1)

Application Number Title Priority Date Filing Date
HK09108961.9A HK1131738A1 (en) 2006-04-27 2009-09-29 Antisecretory protein for use in the treatment of compartment syndrome

Country Status (20)

Country Link
US (2) US8309513B2 (de)
EP (2) EP2363140B1 (de)
JP (2) JP5323682B2 (de)
KR (3) KR101805973B1 (de)
CN (3) CN104689299B (de)
AT (1) ATE526031T1 (de)
AU (1) AU2007244003B2 (de)
BR (2) BRPI0710794A2 (de)
CA (1) CA2650589C (de)
DK (3) DK2037950T3 (de)
ES (3) ES2615515T3 (de)
HK (1) HK1131738A1 (de)
IL (1) IL194774A (de)
MX (1) MX2008013774A (de)
NZ (2) NZ572257A (de)
PL (2) PL2363140T3 (de)
RU (2) RU2465914C2 (de)
SG (1) SG171601A1 (de)
WO (1) WO2007126363A2 (de)
ZA (2) ZA200809116B (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104689299B (zh) 2006-04-27 2020-02-21 兰特门内阿斯-法克托尔公司 抗分泌蛋白对于治疗间室综合症的应用
MX2008013777A (es) 2006-04-27 2009-02-03 Lantmaennen As Faktor Ab Usos medicos adicionales de la proteina antisecretora.
EP2015767B1 (de) 2006-04-27 2016-01-06 Lantmännen AS-Faktor AB Verwendung des antisekretorischen faktors zur behandlung von erhöhtem augeninnendruck
US9220750B2 (en) * 2007-04-27 2015-12-29 Lantmannen As-Faktor Ab Use of antisecretory factors (AF) for optimizing cellular uptake
US9962424B2 (en) 2007-04-27 2018-05-08 Lantmännen As-Faktor Ab Use of antisecretory factors (AF) for optimizing cellular uptake
WO2010065342A1 (en) 2008-11-25 2010-06-10 Temple University Angiocidin inhibition of tumor cell growth
KR20180027582A (ko) * 2015-07-10 2018-03-14 란트만넨 아스-팍토르 아베 Af-16 함량이 높은 난황의 제조 방법
WO2018015379A1 (en) 2016-07-18 2018-01-25 Lantmännen As-Faktor Ab Antisecretory factor 17
WO2020002464A1 (en) 2018-06-28 2020-01-02 Lantmännen Medical Ab Antisecretory factor for use in treatment and/or prevention of acute respiratory failure
CN112770644A (zh) 2018-09-28 2021-05-07 兰特门内保健食品公司 包含麦芽化小麦的可消耗产品
EP3855934A2 (de) 2018-09-28 2021-08-04 Lantmännen Functional Foods AB Verzehrbares produkt mit gemälztem entspelztem hafer
WO2021191431A1 (en) 2020-03-26 2021-09-30 Lantmännen Functional Foods Ab A consumable product comprising malted cereals for promoting recovery at physical activity

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH682716A5 (de) * 1992-01-13 1993-11-15 Christian Fricker Benzo-Pyrone und/oder Dobesilat-Calcium enthaltende pharmazeutische Zusammensetzung.
US5585401A (en) 1994-12-09 1996-12-17 The Reents Of The University Of California Method for enhancing outflow of aqueous humor in treatment of glaucoma
SE508609C2 (sv) 1995-08-24 1998-10-19 Rural Patent Svenska Ab Antisekretorisk faktor - dess aminosyrasekvens, nubleinsyrasekvens och användning
SE506486C2 (sv) 1996-11-20 1997-12-22 Svenska Lantmaennen Riksfoerbu Födoämne som vid förtäring inducerar antisekretoriska proteiner
SE513496C2 (sv) * 1998-12-17 2000-09-18 Rural Patent Svenska Ab NASP-berikad äggula samt dess användning
US7662169B2 (en) * 2000-09-05 2010-02-16 Wittmann Dietmar H Prosthesis and method for lowering abdominal pressure
GB0322645D0 (en) * 2003-09-26 2003-10-29 Melacure Therapeutics Ab Use of antisecretory factor peptides
CN104689299B (zh) 2006-04-27 2020-02-21 兰特门内阿斯-法克托尔公司 抗分泌蛋白对于治疗间室综合症的应用
MX2008013777A (es) 2006-04-27 2009-02-03 Lantmaennen As Faktor Ab Usos medicos adicionales de la proteina antisecretora.
WO2009052478A1 (en) * 2007-10-19 2009-04-23 Trustees Of Boston University Metabolic and cardioprotection by the myokine follistatin-like 1 polypeptide

Also Published As

Publication number Publication date
CA2650589A1 (en) 2007-11-08
ZA200809114B (en) 2009-06-24
CN104689299B (zh) 2020-02-21
CN101460187B (zh) 2014-11-05
AU2007244003A1 (en) 2007-11-08
RU2457853C2 (ru) 2012-08-10
CN101460187A (zh) 2009-06-17
RU2465914C2 (ru) 2012-11-10
KR20140123601A (ko) 2014-10-22
WO2007126363A3 (en) 2008-03-13
ATE526031T1 (de) 2011-10-15
ES2615515T3 (es) 2017-06-07
CN104689299A (zh) 2015-06-10
NZ572257A (en) 2011-10-28
JP5285043B2 (ja) 2013-09-11
MX2008013774A (es) 2009-02-03
IL194774A (en) 2015-07-30
WO2007126363A8 (en) 2008-10-30
US8309513B2 (en) 2012-11-13
PL2363140T3 (pl) 2017-05-31
JP2009535328A (ja) 2009-10-01
KR20140141729A (ko) 2014-12-10
RU2008146731A (ru) 2010-06-10
ES2374712T3 (es) 2012-02-21
ES2472737T3 (es) 2014-07-02
EP2363140B1 (de) 2016-12-14
AU2007244003B2 (en) 2012-08-02
JP2011032284A (ja) 2011-02-17
EP2040734B1 (de) 2011-09-28
BRPI0710794A2 (pt) 2011-06-21
WO2007126363A2 (en) 2007-11-08
PL2040734T3 (pl) 2012-04-30
JP5323682B2 (ja) 2013-10-23
ZA200809116B (en) 2009-07-29
IL194774A0 (en) 2011-08-01
KR101805973B1 (ko) 2017-12-06
DK2040734T3 (da) 2012-01-23
CN101437533A (zh) 2009-05-20
EP2040734A2 (de) 2009-04-01
KR101757523B1 (ko) 2017-07-12
SG171601A1 (en) 2011-06-29
CA2650589C (en) 2017-06-13
US8389468B2 (en) 2013-03-05
KR20090045148A (ko) 2009-05-07
CN101437533B (zh) 2016-10-12
RU2008146734A (ru) 2010-06-10
DK2037950T3 (da) 2014-06-30
US20110305773A1 (en) 2011-12-15
BRPI0710858A2 (pt) 2011-05-17
EP2363140A1 (de) 2011-09-07
US20090185982A1 (en) 2009-07-23
NZ572256A (en) 2012-02-24
DK2363140T3 (en) 2017-03-06

Similar Documents

Publication Publication Date Title
HK1131738A1 (en) Antisecretory protein for use in the treatment of compartment syndrome
CY1124298T1 (el) Φενφλουραμινη για χρηση στην θεραπευτικη αντιμετωπιση του συνδρομου dravet
BR112019021822A2 (pt) Terapia de combinação
EA201890146A1 (ru) СПОСОБЫ ЛЕЧЕНИЯ СОЛИДНЫХ ОПУХОЛЕЙ С ИСПОЛЬЗОВАНИЕМ КОМБИНИРОВАННОЙ ТЕРАПИИ ИНГИБИТОРОМ mTOR В ВИДЕ НАНОЧАСТИЦ
DOP2006000052A (es) Alargar el tiempo hasta la progresión de la enfermedad o la supervivencia de los pacientes de cáncer
JP2009530288A5 (de)
NO20053782L (no) Behandling av kreft med 2-deoksyglukose
DK2305255T3 (da) Arylurinstofforbindelser i kombination med andre cytostatiske eller cytotoksiske midler til behandling af humane cancere
CY1111065T1 (el) Φαρμακευτικη συνθεση που περιεχει μια ωμεγα-καρβοξυαρυλ υποκατεστημενη διφαινυλ ουρια για τη θεραπευτικη αντιμετωπιση του καρκινου
EA201290356A1 (ru) Композиции для лечения тошноты и рвоты центрального происхождения
CL2008001932A1 (es) Compuestos derivados de 6-cicloamino-3-(piridin-4-il)imidazo[1,2-b]piridazina, inhibidores de cq1epsilon y/o ck1delta; procedimiento de preparacion; composicion farmaceutica que los comprende; y uso en el tratamiento de desordenes del sueno, trastorno del ritmo circadiano, cancer y enfermedad de alzheimer.
NO20091661L (no) Anvendelse av pegylert IL-10 for a behandle kreft
EP2571573A4 (de) Kapselphototherapie
ATE511889T1 (de) Partikeltherapieanlage
BR112015026297A2 (pt) terapia combinada composta por um inibidor tor quinase e um composto de 5-quinazolinona substituído para o tratamento de câncer
NZ590550A (en) Inhibitors of Apoptosis (IAP) for treating cancer
CY1117394T1 (el) Λιξισενατιδη για χρηση στην θεραπευτικη αντιμετωπιση της στενωσης ή/και αποφραξης στο συστημα παγκρεατικων πορων
MY192081A (en) Cancer treatments
BR112015026247A2 (pt) métodos para o tratamento de câncer com o uso de terapia combinada com inibidor de cinase tor
EA201300421A1 (ru) Комбинированная терапия для лечения инфекции hcv
MX2008002456A (es) Uso de ambroxol para el tratamiento de infecciones por rinovirus.
NO20064753L (no) Kombinasjonsterapi
EA201201338A1 (ru) Способы лечения комбинированных лучевых и тепловых поражений
WO2011056566A3 (en) Compounds and methods for treatment of cancer
DK1720540T3 (da) Satraplatin til behandling af resistente tumorer eller tumorer, der er vanskelige at behandle

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20210424